LL-37 vs Alpha-Defensins

Overview

LL-37 and Alpha-Defensins are both endogenous human antimicrobial peptides (AMPs) that form part of the innate immune defense system. LL-37 is the only human cathelicidin, while alpha-defensins are a family of six peptides (HNP-1 through 4 and HD-5, HD-6). Both classes show broad-spectrum antimicrobial activity and immunomodulatory effects, making them targets for therapeutic development.

Key Facts

Aspect	LL-37	Alpha-Defensins
Type	Cathelicidin	Defensin family
Family Members	1 (LL-37 only)	6 (HNP-1-4, HD-5, HD-6)
Structure	37 amino acids	29-35 amino acids
Net Charge	+6	+3 to +5
Source	Neutrophils, epithelia	Neutrophils, Paneth cells
FDA Status	Not approved	Not approved

Structural Comparison

Aspect	LL-37	Alpha-Defensins
Secondary Structure	Alpha-helical	Beta-sheet
Disulfide Bonds	None	3 (characteristic)
Amphipathicity	Yes	Yes
Cationic Nature	Yes	Yes

LL-37 Structure

• Linear alpha-helical peptide
• C-terminal of hCAP-18 precursor
• Amphipathic helix structure
• No disulfide bonds

Alpha-Defensin Structure

• Triple-stranded beta-sheet
• Conserved 6-cysteine/3-disulfide pattern
• Compact globular shape
• Stable structure

Expression and Sources

Source	LL-37	Alpha-Defensins
Neutrophils	Yes	Yes (HNP-1-4)
Epithelial cells	Yes	Limited
Paneth cells	No	Yes (HD-5, HD-6)
Macrophages	Induced	Limited
Keratinocytes	Induced	No

Tissue Distribution

Location	LL-37	Alpha-Defensins
Skin	Induced in wounds	Minimal
Respiratory	Constitutive + induced	Some
Gut	Limited	HD-5, HD-6 (Paneth)
Neutrophils	Azurophil granules	Primary granules

Mechanism Comparison

Aspect	LL-37	Alpha-Defensins
Primary Action	Membrane disruption	Membrane disruption
Immunomodulation	Strong	Moderate
LPS Neutralization	Yes	Some
Chemotaxis	Yes	Yes

LL-37 Mechanisms

1. Direct Antimicrobial

   • Membrane permeabilization
   • Disrupts bacterial integrity
   • Broad spectrum activity
   • Kills bacteria, fungi, viruses

2. Immunomodulation

   • Chemoattractant for immune cells
   • Cytokine modulation
   • Wound healing promotion
   • Angiogenesis stimulation

3. LPS Neutralization

   • Binds lipopolysaccharide
   • Reduces septic response
   • Anti-inflammatory effect

Alpha-Defensin Mechanisms

1. Direct Antimicrobial

   • Pore formation in membranes
   • Intracellular target disruption
   • Broad spectrum activity
   • Some selectivity for bacteria

2. Gut Defense (HD-5, HD-6)

   • Paneth cell secretion
   • Gut microbiome shaping
   • Enteric pathogen defense
   • HD-6 forms nanonets

3. Immunomodulation

   • Chemotactic activity
   • Adaptive immunity bridge
   • Mast cell activation

Antimicrobial Spectrum

LL-37 Activity

Target	Activity Level
Gram-positive bacteria	Strong
Gram-negative bacteria	Strong
Fungi	Moderate
Viruses	Some (membrane-enveloped)
Biofilms	Active

Alpha-Defensin Activity

Target	HNP-1-4	HD-5, HD-6
Gram-positive	Strong	Strong
Gram-negative	Moderate	Moderate
Fungi	Some	Some
Parasites	Some	Some

Evidence for Therapeutic Use

Factor	LL-37	Alpha-Defensins
In Vitro Studies	Extensive	Extensive
Animal Studies	Multiple	Multiple
Human Trials	Few/early	Very few
Overall Evidence	Low-Moderate	Low

LL-37 Research Status

Area	Status
Wound healing	Preclinical promising
Topical infections	Early research
Respiratory	Being studied
Cancer	Some interest

Alpha-Defensin Research

Area	Status
Gut infections	HD-5, HD-6 research
Neutrophil function	Biomarker studies
Inflammatory disease	Correlation studies
Therapeutic development	Limited

Clinical Relevance

Disease Associations

Condition	LL-37	Alpha-Defensins
Psoriasis	Elevated (pathogenic role)	Elevated
Crohn’s disease	Variable	Reduced Paneth cell
Cystic fibrosis	Impaired function	Present
Sepsis	Biomarker	Biomarker

Deficiency States

Condition	LL-37 Impact	Defensin Impact
Morbus Kostmann	Reduced	HNP reduced
HIV/AIDS	May be reduced	Variable
Malnutrition	May be impaired	May be impaired

Administration Challenges

LL-37

Challenge	Issue
Stability	Susceptible to proteases
Cost	Expensive synthesis
Delivery	Requires careful formulation
Toxicity	High doses may be hemolytic

Alpha-Defensins

Challenge	Issue
Synthesis	Complex (disulfide bonds)
Folding	Requires proper disulfide formation
Stability	Better than LL-37
Selectivity	Some host cell effects

Analogs and Modifications

LL-37 Derivatives

Analog	Purpose
LL-37 fragments	Improved stability
D-amino acid versions	Protease resistance
Cyclized variants	Enhanced activity

Defensin Modifications

Approach	Status
Linearized versions	Studied
Sequence modifications	Active research
Fusion proteins	Being developed

Regulatory Status

Aspect	LL-37	Alpha-Defensins
FDA Approval	None	None
Clinical Trials	Very few	Very few
Drug Development	Early stage	Early stage
Availability	Research chemical	Research chemical

Summary

Factor	LL-37	Alpha-Defensins
Structure	Alpha-helix (37 AA)	Beta-sheet (29-35 AA)
Family Size	Single peptide	6 peptides
Main Sources	Neutrophils, epithelia	Neutrophils, Paneth cells
Disulfide Bonds	None	3 (conserved)
Immunomodulation	Strong	Moderate
Therapeutic Stage	Early research	Early research

Key Takeaways

1. Different structures: LL-37 is alpha-helical; defensins are beta-sheet
2. Both are endogenous: Natural human antimicrobial peptides
3. LL-37 is single: One cathelicidin vs 6 alpha-defensins
4. Different sources: LL-37 broader; defensins include gut-specific
5. Both have immunomodulatory effects: Beyond direct killing
6. Neither approved therapeutically: Both in early research
7. Stability challenges: Both have delivery/stability issues
8. Therapeutic potential: Both being studied but far from clinical use

---

This comparison is for educational purposes only. Neither LL-37 nor alpha-defensins are approved for therapeutic use. Both are research compounds.